{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:55:29Z","timestamp":1774623329849,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Hei Longjiang Postdoctoral Foundation","award":["LBH-Z16120"],"award-info":[{"award-number":["LBH-Z16120"]}]},{"name":"the Hai Yan Science Foundation of Harbin Medical University Cancer Hospital","award":["JJZD2019-05"],"award-info":[{"award-number":["JJZD2019-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02240-9","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:05:55Z","timestamp":1771657555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Nana","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchao","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangshuang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zibo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"3","key":"2240_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2240_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092483","author":"E Kjeldsted","year":"2023","unstructured":"Kjeldsted E, Gehl J, S\u00f8rensen DM, Lodin A, Ceballos SG, Dalton SO. Patient-related characteristics associated with treatment modifications and suboptimal relative dose intensity of neoadjuvant chemotherapy in patients with breast cancer-a retrospective study. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15092483.","journal-title":"Cancers"},{"issue":"4785","key":"2240_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):177\u201382.","journal-title":"Science"},{"issue":"5","key":"2240_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/bjc.1994.405","volume":"70","author":"R Colomer","year":"1994","unstructured":"Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer. 1994;70(5):819\u201325.","journal-title":"Br J Cancer"},{"issue":"3","key":"2240_CR5","first-page":"560","volume":"60","author":"H Roh","year":"2000","unstructured":"Roh H, Pippin J, Drebin JA. Down-regulation of HER2\/neu expression induces apoptosis in human cancer cells that overexpress HER2\/neu. Cancer Res. 2000;60(3):560\u20135.","journal-title":"Cancer Res"},{"issue":"10","key":"2240_CR6","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2240_CR7","first-page":"1550","volume":"50","author":"BM Fendly","year":"1990","unstructured":"Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2\/neu gene product. Cancer Res. 1990;50(5):1550\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"2240_CR8","first-page":"85","volume":"1","author":"DW Rusnak","year":"2001","unstructured":"Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1(2):85\u201394.","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"2240_CR9","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","volume":"23","author":"SL Moulder","year":"2017","unstructured":"Moulder SL, Borges VF, Baetz T, McSpadden T, Fernetich G, Murthy RK, et al. Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC). Clin Cancer Res. 2017;23(14):3529\u201336.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2240_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ardp.200800009","volume":"341","author":"A Wissner","year":"2008","unstructured":"Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim). 2008;341(8):465\u201377.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"23","key":"2240_CR11","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.22.00519","volume":"40","author":"SH Giordano","year":"2022","unstructured":"Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(23):2612\u201335.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2240_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"key":"2240_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2020.06.025","volume":"491","author":"D Rong","year":"2020","unstructured":"Rong D, Wang C, Zhang X, Wei Y, Zhang M, Liu D, et al. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells. Cancer Lett. 2020;491:36\u201349.","journal-title":"Cancer Lett"},{"key":"2240_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.canlet.2019.08.008","volume":"464","author":"N Qiu","year":"2019","unstructured":"Qiu N, He YF, Zhang SM, Zhan YT, Han GD, Jiang M, et al. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K\/AKT pathway. Cancer Lett. 2019;464:25\u201336.","journal-title":"Cancer Lett"},{"issue":"6","key":"2240_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.tibs.2022.02.003","volume":"47","author":"PR Smith","year":"2022","unstructured":"Smith PR, Pandit SC, Loerch S, Campbell ZT. The space between notes: emerging roles for translationally silent ribosomes. Trends Biochem Sci. 2022;47(6):477\u201391.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2240_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrm1551","volume":"6","author":"RJ White","year":"2005","unstructured":"White RJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol. 2005;6(1):69\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2240_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1042\/bss0730141","volume":"73","author":"N Gomez-Roman","year":"2006","unstructured":"Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, Athineos D, Zhang J, et al. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem Soc Symp. 2006;73:141\u201354.","journal-title":"Biochem Soc Symp"},{"key":"2240_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010055","author":"M Penzo","year":"2019","unstructured":"Penzo M, Montanaro L, Trer\u00e9 D, Derenzini M. The ribosome biogenesis-cancer connection. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8010055.","journal-title":"Cells"},{"key":"2240_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010140","author":"A Russo","year":"2017","unstructured":"Russo A, Russo G. Ribosomal proteins control or bypass p53 during nucleolar stress. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18010140.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2240_CR20","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1002\/jcp.27722","volume":"234","author":"G Molavi","year":"2019","unstructured":"Molavi G, Samadi N, Hosseingholi EZ. The roles of moonlight ribosomal proteins in the development of human cancers. J Cell Physiol. 2019;234(6):8327\u201341.","journal-title":"J Cell Physiol"},{"issue":"9","key":"2240_CR21","first-page":"2194","volume":"63","author":"MA Dressman","year":"2003","unstructured":"Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM, et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res. 2003;63(9):2194\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"2240_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1677\/erc.1.01147","volume":"13","author":"P Kauraniemi","year":"2006","unstructured":"Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 2006;13(1):39\u201349.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2240_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ctrv.2006.10.001","volume":"33","author":"MS Mano","year":"2007","unstructured":"Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev. 2007;33(1):64\u201377.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2240_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022672","volume":"6","author":"A Bee","year":"2011","unstructured":"Bee A, Brewer D, Beesley C, Dodson A, Forootan S, Dickinson T, et al. SiRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer. PLoS ONE. 2011;6(7):e22672.","journal-title":"PLoS ONE"},{"issue":"7 Pt 1","key":"2240_CR25","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-05-2445","volume":"12","author":"A Bee","year":"2006","unstructured":"Bee A, Ke Y, Forootan S, Lin K, Beesley C, Forrest SE, et al. Ribosomal protein l19 is a prognostic marker for human prostate cancer. Clin Cancer Res. 2006;12(7 Pt 1):2061\u20135.","journal-title":"Clin Cancer Res"},{"issue":"5b","key":"2240_CR26","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1111\/j.1582-4934.2008.00253.x","volume":"12","author":"CJ Huang","year":"2008","unstructured":"Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, Cheng YC, et al. Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med. 2008;12(5b):1936\u201343.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2240_CR27","first-page":"217","volume":"14","author":"M Leirdal","year":"2004","unstructured":"Leirdal M, Shadidy M, R\u00f8sok \u00d8, Sioud M. Identification of genes differentially expressed in breast cancer cell line SKBR3: potential identification of new prognostic biomarkers. Int J Mol Med. 2004;14(2):217\u201322.","journal-title":"Int J Mol Med"},{"issue":"3","key":"2240_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41435-020-0095-7","volume":"21","author":"LEM Heeb","year":"2020","unstructured":"Heeb LEM, Egholm C, Boyman O. Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils. Genes Immun. 2020;21(3):143\u20139.","journal-title":"Genes Immun"},{"issue":"3","key":"2240_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14712598.2020.1714027","volume":"20","author":"A Moran","year":"2020","unstructured":"Moran A, Pavord ID. Anti-IL-4\/IL-13 for the treatment of asthma: the story so far. Expert Opin Biol Ther. 2020;20(3):283\u201394.","journal-title":"Expert Opin Biol Ther"},{"issue":"18","key":"2240_CR30","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","volume":"125","author":"LJ Geskin","year":"2015","unstructured":"Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798\u2013805.","journal-title":"Blood"},{"issue":"4","key":"2240_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000049523","volume":"126","author":"BF Skinnider","year":"2001","unstructured":"Skinnider BF, Kapp U, Mak TW. Interleukin 13: a growth factor in hodgkin lymphoma. Int Arch Allergy Immunol. 2001;126(4):267\u201376.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"2240_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/BF02305798","volume":"3","author":"BJ Camp","year":"1996","unstructured":"Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol. 1996;3(2):176\u201384.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2240_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.11613\/BM.2011.021","volume":"21","author":"N Srabovici","year":"2011","unstructured":"Srabovici N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Softic A, Begic L. Interleukin 13 expression in the primary breast cancer tumour tissue. Biochem Med (Zagreb). 2011;21(2):131\u20138.","journal-title":"Biochem Med (Zagreb)"},{"issue":"5","key":"2240_CR34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/jcb.25399","volume":"117","author":"X Yan","year":"2016","unstructured":"Yan X, Li W, Pan L, Fu E, Xie Y, Chen M, et al. Lewis lung cancer cells promote SIGNR1(CD209b)-mediated macrophages polarization induced by IL-4 to facilitate immune evasion. J Cell Biochem. 2016;117(5):1158\u201366.","journal-title":"J Cell Biochem"},{"issue":"1","key":"2240_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0708-7","volume":"12","author":"X Lin","year":"2019","unstructured":"Lin X, Wang S, Sun M, Zhang C, Wei C, Yang C, et al. MiR-195-5p\/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. J Hematol Oncol. 2019;12(1):20.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2240_CR36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00384-012-1456-0","volume":"27","author":"A Formentini","year":"2012","unstructured":"Formentini A, Braun P, Fricke H, Link KH, Henne-Bruns D, Kornmann M. Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer. Int J Colorectal Dis. 2012;27(10):1369\u201376.","journal-title":"Int J Colorectal Dis"},{"issue":"7","key":"2240_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/07357907.2015.1041642","volume":"33","author":"S Aziz","year":"2015","unstructured":"Aziz S, Ahmed SS, Ali A, Khan FA, Zulfiqar G, Iqbal J, et al. Salivary Immunosuppressive Cytokines IL-10 and IL-13 Are Significantly Elevated in Oral Squamous Cell Carcinoma Patients. Cancer Invest. 2015;33(7):318\u201328.","journal-title":"Cancer Invest"},{"issue":"1a","key":"2240_CR38","first-page":"125","volume":"19","author":"M Kornmann","year":"1999","unstructured":"Kornmann M, Kleeff J, Debinski W, Korc M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res. 1999;19(1a):125\u201331.","journal-title":"Anticancer Res"},{"key":"2240_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222112008","author":"WJ Wu","year":"2021","unstructured":"Wu WJ, Wang SH, Wu CC, Su YA, Chiang CY, Lai CH, et al. IL-4 and IL-13 promote proliferation of mammary epithelial cells through STAT6 and IRS-1. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222112008.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2240_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02276-z","volume":"24","author":"K Ranjan","year":"2025","unstructured":"Ranjan K, Rajendran BK, Deen IU, Costantini A, de Rodas ML, Desai SS, et al. IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. Mol Cancer. 2025;24(1):80.","journal-title":"Mol Cancer"},{"issue":"1","key":"2240_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49667-2","volume":"15","author":"L Yu","year":"2024","unstructured":"Yu L, Deng Y, Wang X, Santos C, Davis IJ, Earp HS, et al. Co-targeting JAK1\/STAT6\/GAS6\/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. Nat Commun. 2024;15(1):5292.","journal-title":"Nat Commun"},{"issue":"11","key":"2240_CR42","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13238-011-1113-3","volume":"2","author":"Q Meng","year":"2011","unstructured":"Meng Q, Xia Y. C-Jun, at the crossroad of the signaling network. Protein Cell. 2011;2(11):889\u201398.","journal-title":"Protein Cell"},{"key":"2240_CR43","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20140141","author":"YY Zhou","year":"2015","unstructured":"Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK\/JNK signalling: a potential autophagy regulation pathway. 2015. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20140141."},{"issue":"10","key":"2240_CR44","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.18632\/oncotarget.3482","volume":"6","author":"WC Chang","year":"2015","unstructured":"Chang WC, Wu SL, Huang WC, Hsu JY, Chan SH, Wang JM, et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget. 2015;6(10):7741\u201357.","journal-title":"Oncotarget"},{"issue":"4","key":"2240_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2474-4","volume":"11","author":"J Lin","year":"2020","unstructured":"Lin J, Ding S, Xie C, Yi R, Wu Z, Luo J, et al. MicroRNA-4476 promotes glioma progression through a miR-4476\/APC\/\u03b2-catenin\/c-Jun positive feedback loop. Cell Death Dis. 2020;11(4):269.","journal-title":"Cell Death Dis"},{"key":"2240_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-145","volume":"7","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Pu X, Shi M, Chen L, Song Y, Qian L, et al. Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer. 2007;7:145.","journal-title":"BMC Cancer"},{"issue":"13 Spec No","key":"2240_CR47","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0959-8049(00)00175-1","volume":"36","author":"BW Ozanne","year":"2000","unstructured":"Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, et al. Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer. 2000;36(13 Spec No):1640\u20138.","journal-title":"Eur J Cancer"},{"issue":"44","key":"2240_CR48","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1038\/sj.onc.1202989","volume":"18","author":"LM Smith","year":"1999","unstructured":"Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999;18(44):6063\u201370.","journal-title":"Oncogene"},{"issue":"3","key":"2240_CR49","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I","volume":"81","author":"TJ Bos","year":"1999","unstructured":"Bos TJ, Margiotta P, Bush L, Wasilenko W. Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun over-expression. Int J Cancer. 1999;81(3):404\u201310.","journal-title":"Int J Cancer"},{"issue":"13","key":"2240_CR50","first-page":"5168","volume":"61","author":"DA Zajchowski","year":"2001","unstructured":"Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 2001;61(13):5168\u201378.","journal-title":"Cancer Res"},{"issue":"4","key":"2240_CR51","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1083\/jcb.143.4.1087","volume":"143","author":"A Malliri","year":"1998","unstructured":"Malliri A, Symons M, Hennigan RF, Hurlstone AF, Lamb RF, Wheeler T, et al. The transcription factor AP-1 is required for EGF-induced activation of rho-like GTPases, cytoskeletal rearrangements, motility, and in vitro invasion of A431 cells. J Cell Biol. 1998;143(4):1087\u201399.","journal-title":"J Cell Biol"},{"issue":"1","key":"2240_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevi\u0107 S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18(1):51\u201363.","journal-title":"Nat Rev Cancer"},{"issue":"7224","key":"2240_CR53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nature07449","volume":"456","author":"M Barna","year":"2008","unstructured":"Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971\u20135.","journal-title":"Nature"},{"issue":"1","key":"2240_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40425-019-0539-7","volume":"7","author":"HJ Park","year":"2019","unstructured":"Park HJ, Jang GY, Kim YS, Park JH, Lee SE, Vo MC, et al. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine. J Immunother Cancer. 2019;7(1):60.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2240_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1349-7006.2009.01351.x","volume":"101","author":"K Kuroda","year":"2010","unstructured":"Kuroda K, Takenoyama M, Baba T, Shigematsu Y, Shiota H, Ichiki Y, et al. Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma. Cancer Sci. 2010;101(1):46\u201353.","journal-title":"Cancer Sci"},{"key":"2240_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.686547","volume":"9","author":"B Rao","year":"2021","unstructured":"Rao B, Li J, Ren T, Yang J, Zhang G, Liu L, et al. RPL19 is a prognostic biomarker and promotes tumor progression in hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:686547.","journal-title":"Front Cell Dev Biol"},{"key":"2240_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2021.08.007","volume":"60","author":"P Mand\u00f3","year":"2021","unstructured":"Mand\u00f3 P, Rivero SG, Rizzo MM, Pinkasz M, Levy EM. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast. 2021;60:15\u201325.","journal-title":"Breast"},{"issue":"Suppl 1","key":"2240_CR58","first-page":"21","volume":"10","author":"M Luque-Cabal","year":"2016","unstructured":"Luque-Cabal M, Garc\u00eda-Teijido P, Fern\u00e1ndez-P\u00e9rez Y, S\u00e1nchez-Lorenzo L, Palacio-V\u00e1zquez I. Mechanisms behind the resistance to Trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol. 2016;10(Suppl 1):21\u201330.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"2240_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4(1):11\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2240_CR60","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.4049\/jimmunol.148.6.1812","volume":"148","author":"DF Mangan","year":"1992","unstructured":"Mangan DF, Robertson B, Wahl SM. IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. J Immunol. 1992;148(6):1812\u20136.","journal-title":"J Immunol"},{"issue":"2","key":"2240_CR61","doi-asserted-by":"publisher","first-page":"887","DOI":"10.4049\/jimmunol.170.2.887","volume":"170","author":"P Shankaranarayanan","year":"2003","unstructured":"Shankaranarayanan P, Nigam S. IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor gamma transcription factor. J Immunol. 2003;170(2):887\u201394.","journal-title":"J Immunol"},{"issue":"40","key":"2240_CR62","doi-asserted-by":"publisher","first-page":"28743","DOI":"10.1074\/jbc.M113.499053","volume":"288","author":"HD Kim","year":"2013","unstructured":"Kim HD, Yu SJ, Kim HS, Kim YJ, Choe JM, Park YG, et al. Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK. J Biol Chem. 2013;288(40):28743\u201354.","journal-title":"J Biol Chem"},{"issue":"7","key":"2240_CR63","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1096\/fj.06-6319com","volume":"21","author":"L Aoudjehane","year":"2007","unstructured":"Aoudjehane L, Podevin P, Scatton O, Jaffray P, Dusanter-Fourt I, Feldmann G, et al. Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway. FASEB J. 2007;21(7):1433\u201344.","journal-title":"FASEB J"},{"issue":"18","key":"2240_CR64","first-page":"4199","volume":"58","author":"JL Gooch","year":"1998","unstructured":"Gooch JL, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 1998;58(18):4199\u2013205.","journal-title":"Cancer Res"},{"issue":"16","key":"2240_CR65","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1073\/pnas.89.16.7836","volume":"89","author":"C Schindler","year":"1992","unstructured":"Schindler C, Fu XY, Improta T, Aebersold R, Darnell JE Jr. Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA. 1992;89(16):7836\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2240_CR66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00280-008-0881-9","volume":"63","author":"F Mbeunkui","year":"2009","unstructured":"Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2240_CR67","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396.","journal-title":"Nat Immunol"},{"issue":"1","key":"2240_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49\u201361.","journal-title":"Immunity"},{"issue":"16","key":"2240_CR69","doi-asserted-by":"publisher","first-page":"7840","DOI":"10.1073\/pnas.89.16.7840","volume":"89","author":"XY Fu","year":"1992","unstructured":"Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE Jr. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A. 1992;89(16):7840\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2240_CR70","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.imlet.2021.02.006","volume":"233","author":"W Wang","year":"2021","unstructured":"Wang W, Wang L, Zha B. The roles of STAT6 in regulating B cell fate, activation, and function. Immunol Lett. 2021;233:87\u201391.","journal-title":"Immunol Lett"},{"issue":"8","key":"2240_CR71","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","volume":"33","author":"MK Kuepper","year":"2019","unstructured":"Kuepper MK, B\u00fctow M, Herrmann O, Ziemons J, Chatain N, Maurer A, et al. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 2019;33(8):1964\u201377.","journal-title":"Leukemia"},{"key":"2240_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02638","volume":"10","author":"C Fu","year":"2019","unstructured":"Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang W, et al. Activation of the IL-4\/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells. Front Immunol. 2019;10:2638.","journal-title":"Front Immunol"},{"issue":"14","key":"2240_CR73","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/pros.20640","volume":"67","author":"S Das","year":"2007","unstructured":"Das S, Roth CP, Wasson LM, Vishwanatha JK. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 2007;67(14):1550\u201364.","journal-title":"Prostate"},{"issue":"2","key":"2240_CR74","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.bmc.2006.10.015","volume":"15","author":"S Nagashima","year":"2007","unstructured":"Nagashima S, Yokota M, Nakai E, Kuromitsu S, Ohga K, Takeuchi M, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007;15(2):1044\u201355.","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"2240_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.23","volume":"6","author":"G Nappo","year":"2017","unstructured":"Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, et al. The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis. 2017;6(5):e342.","journal-title":"Oncogenesis"},{"issue":"3","key":"2240_CR76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0092-8674(88)90024-4","volume":"55","author":"T Curran","year":"1988","unstructured":"Curran T, Franza BR Jr. Fos and jun: the AP-1 connection. Cell. 1988;55(3):395\u20137.","journal-title":"Cell"},{"issue":"15","key":"2240_CR77","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","volume":"21","author":"S Mathas","year":"2002","unstructured":"Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21(15):4104\u201313.","journal-title":"EMBO J"},{"issue":"13","key":"2240_CR78","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res. 2022;82(13):2344\u201353.","journal-title":"Cancer Res"},{"issue":"1","key":"2240_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6(1):323.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2240_CR80","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2240_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7129","volume":"13","author":"Y Li","year":"2024","unstructured":"Li Y, Wang S, Li G, Gao C, Cui Z, Cong M, et al. The RNA-binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA. Cancer Med. 2024;13(7):e7129.","journal-title":"Cancer Med"},{"issue":"2","key":"2240_CR82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1039\/C2FO30156C","volume":"4","author":"W Chanput","year":"2013","unstructured":"Chanput W, Mes JJ, Savelkoul HF, Wichers HJ. Characterization of polarized THP-1 macrophages and polarizing ability of LPS and food compounds. Food Funct. 2013;4(2):266\u201376.","journal-title":"Food Funct"},{"issue":"36","key":"2240_CR83","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1038\/onc.2013.395","volume":"33","author":"F Bengsch","year":"2014","unstructured":"Bengsch F, Buck A, G\u00fcnther SC, Seiz JR, Tacke M, Pfeifer D, et al. Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene. 2014;33(36):4474\u201384.","journal-title":"Oncogene"},{"issue":"1","key":"2240_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0396-x","volume":"35","author":"Y Liu","year":"2016","unstructured":"Liu Y, Jin X, Li Y, Ruan Y, Lu Y, Yang M, et al. DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac. J Exp Clin Cancer Res. 2016;35(1):120.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02240-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02240-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:02:49Z","timestamp":1774620169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02240-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02240-9","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20140141","asserted-by":"subject"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the Ethics Committee of Harbin Medical University Cancer Hospital.The date and reference number of the ethical approval: February 10, 2023 and KY2023-20.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The privacy rights of human subjects have been observed and that informed consent was obtained for experimentation with human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors affirm that research participants provided informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}